In September 1997, both fenfluramine and dexfenfluramine were withdrawn from the United States (US) market.

Pergolide was withdrawn from the USÂ market in August 2007 because of its association with increased risk for valvulopathy.

Although rarely used now because of their adverse effects, methysergide and ergotamine remain licensed for migraine prophylaxis.